Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.8052W HIGH $8.00
Volume
1.73 M
Value Traded
8.45 M
Short % Float
15.59%
-2.59%Week
-16.71%1 Month
-47.44%3 Month
-54.07%6 Month
-81.38%5 Year
-73.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
361.61 M
EPS (TTM)
-0.58
P/E Ratio
-
Ent. Value
143.88 M
Total Shares
106.67 M
Float Shares
92.79 M
Insiders
13.01%
Institutions
84.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RLMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Relmada Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Relmada Therapeutics, Inc.
239Total events
4Upcoming
60Tier-1 (high impact)
2014 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Runway Guidance UpdateCorporate
Cash balance of $217.7 million expected to fund operations through 2029
▲Quarterly UpdateCorporate
Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes
▲Management ChangeCorporate
Appointment of Michael Quirk as Senior Advisor for Sepranolone Program
◆Oral PresentationPresentation
Relmada Therapeutics to present at Jefferies Global Healthcare Conference
◆Trial InitiationNDV-01Trial
Phase 3 RESCUE registrational program initiation
Intermediate-Risk NMIBCsource ↗
◆Oral PresentationNDV-01Presentation
Trials-in-Progress oral presentation of Phase 3 RESCUE program overview at AUA2026
Intermediate-Risk NMIBCsource ↗
◆Poster PresentationNDV-01Presentation
Poster presentation of 12-month Phase 2 data in High-Risk NMIBC at AUA2026
High-Risk NMIBCsource ↗
▲Full ResultsNDV-01Clinical Data
Positive 12-month Phase 2 data for NDV-01 in NMIBC
high-risk non-muscle invasive bladder cancer (NMIBC)source ↗
●Oral PresentationNDV-01Presentation
Phase 3 RESCUE program design presentation at AUA2026
non-muscle invasive bladder cancer (NMIBC)source ↗
◆IND ClearanceNDV-01IND
Expected US IND clearance for NDV-01
non-muscle invasive bladder cancer (NMIBC)source ↗
●Trial InitiationNDV-01Trial
Initiation of Phase 3 RESCUE registrational program for NDV-01
non-muscle invasive bladder cancer (NMIBC)source ↗
◆Trial InitiationsepranoloneTrial
Sepranolone Phase 2 initiation in Prader-Willi syndrome
Prader-Willi syndromesource ↗
▲Patent GrantedNDV-01IP / Competition
Filed provisional patent application with USPTO for NDV-01 formulations and methods of treatment
◆Oral PresentationPresentation
Relmada Therapeutics to present at Leerink Partners Global Healthcare Conference
▲Interim AnalysisNDV-01Trial
12-month interim data from Phase 2 trial of NDV-01
high-risk non-muscle invasive bladder cancer (NMIBC)source ↗
▲Full ResultsNDV-01Clinical Data
Positive 12-month Phase 2 data for NDV-01 in NMIBC
non-muscle invasive bladder cancer (NMIBC)source ↗
▲FDA Feedback ReceivedNDV-01FDA Meeting
FDA written feedback supports randomized-to-observation registrational trial for NDV-01 in intermediate-risk NMIBC
intermediate-risk NMIBC in adjuvant settingsource ↗
◆Trial InitiationNDV-01Trial
Phase 3 registrational trial initiation expected in 1H 2026 for NDV-01 in high-grade NMIBC with CIS
2nd-line refractory high-grade NMIBC with CISsource ↗
●Trial InitiationsepranoloneTrial
Initiation of Phase 2 study for sepranolone in Prader-Willi syndrome
Prader-Willi syndromesource ↗
◆Poster PresentationNDV-01Presentation
Poster presentation of 6-month follow-up data from Phase 2 study of NDV-01 at SUO 2025
non-muscle invasive bladder cancer (NMIBC)source ↗
▲Full ResultsNDV-01Clinical Data
Positive 9-month follow-up data for NDV-01 showed 92% overall response rate at any time in NMIBC
non-muscle invasive bladder cancer (NMIBC)source ↗
▲FDA Feedback ReceivedNDV-01FDA Meeting
FDA alignment on key elements of Phase 3 program with two independent paths for approval
non-muscle invasive bladder cancer (NMIBC)source ↗
●Oral PresentationPresentation
Conference call and webcast to discuss Q3 2025 results and pipeline progress
▼Equity OfferingCorporate
Completed $100M underwritten offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Pricing of $100 million underwritten offering of common stock and pre-funded warrants
▲FDA Feedback ReceivedNDV-01FDA Meeting
FDA feedback supporting 2 registrational study paths for NDV-01 in NMIBC
non-muscle invasive bladder cancersource ↗
▲Full ResultsNDV-01Clinical Data
9-month follow-up safety and efficacy data for NDV-01 in NMIBC
non-muscle invasive bladder cancersource ↗
◆Trial InitiationsepranoloneTrial
Phase 2b study in Tourette syndrome expected to begin around year-end 2025 or Q1 2026
Tourette syndromesource ↗
▲Full ResultsNDV-01Clinical Data
Six-month follow-up data from Phase 2 study of NDV-01 showed 91% complete response rate
NMIBCsource ↗
▲Full ResultsNDV-01Clinical Data
6-month follow-up safety and efficacy data for NDV-01 in NMIBC
non-muscle invasive bladder cancersource ↗
●Enrollment UpdateNDV-01Trial
Enrollment continues in Phase 2 study of NDV-01
non-muscle invasive bladder cancersource ↗
◆Additional DataNDV-01Clinical Data
Updated safety and efficacy data for NDV-01 presented in August 2025
non-muscle invasive bladder cancersource ↗
▲Oral PresentationNDV-01Presentation
Positive initial Phase 2 proof-of-concept data for NDV-01 presented at AUA 2025
non-muscle invasive bladder cancersource ↗
▲Oral PresentationNDV-01Presentation
Positive Phase 2 data presented at AUA 2025
non-muscle invasive bladder cancer (NMIBC)source ↗
◆Poster PresentationNDV-01Presentation
Presentation of NDV-01 Phase 2 data at AUA2025
High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)source ↗
●R&D DayNDV-01Presentation
Investor event to review NDV-01 data
non-muscle invasive bladder cancer (NMIBC)source ↗
◆Topline ReadoutNDV-01Clinical Data
Topline efficacy and safety data from Phase 2 NDV-01 study
high-grade non-muscle invasive bladder cancersource ↗
◆Topline ReadoutNDV-01Clinical Data
Topline data from first 20 patients in Phase 2 study expected at AUA 2025
High-Grade Non-Muscle Invasive Bladder Cancer (HG-NMIBC)source ↗
Past FDA Catalysts and PDUFA Decisions
How RLMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | NDV-01 | IND Clearance | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$281M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
0.8x
rNPV / MCap
Top 40%
Micro Cap(rank 265 of 660)
Percentile Rank
Relmada Therapeutics, Inc. carries a moderate pipeline score (40/100), with $703M risk-adjusted pipeline value, led by REL-1017 in Major Depressive Disorder (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REL-1017 Small moleculeCompletedNCT03051256 | Major Depressive Disorder | Phase 3 | COMPLETED | 1,148 | Sep 30, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every RLMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shenouda MagedOfficer (Chief Financial Officer) | Buy | 79,800 1,000,000 held | $4.25 | 09/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RLMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| VR Adviser, LLC | 1.4 % (7.7 %) | 47.36 M | 6.84 M | 41.31% ( 2.00 M) |
RLMD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-05-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RLMD ranks across every disease it competes in
Competitive Position is a premium feature
See how RLMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRLMD News
RLMDRelmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Relmada Therapeutics will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston from September 8-10, 2026. The company aims to engage with investors and discuss its innovative therapies for oncology and central nervous system disorders. This participation underscores Relmada's commitment to advancing its clinical-stage pipeline.
Read more →RLMD▼ -8%on this news
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics reported its financial results for Q2 2026, highlighting advancements in its drug development pipeline, including NDV-01 and sepranolone. The company expects to file INDs for both drugs by year-end 2026 and initiate respective clinical trials upon clearance. Relmada also appointed Bipin Dalmia as Chief Business Officer and reported a cash balance sufficient to fund operations through 2029.
Read more →RLMDRelmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
Relmada Therapeutics has appointed Bipin Dalmia as Chief Business Officer to lead corporate strategy and business development. Dalmia, with nearly three decades of experience in biopharmaceuticals, will focus on advancing NDV-01, a novel therapy for non-muscle invasive bladder cancer (NMIBC). His expertise is expected to strengthen Relmada's capabilities and support the product's late-stage development.
Read more →RLMD▼ -12.1%on this news
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Relmada Therapeutics, a clinical-stage biotechnology company, will report its second quarter financial results on August 6, 2026. The conference call will provide insights into the company's recent business progress and its ongoing development of therapies for oncology and central nervous system disorders. Interested parties can access the call via a dial-in number or webcast.
Read more →RLMDRelmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
Relmada Therapeutics announced its inclusion in the Russell 2000 and Russell 3000 Indexes, effective June 26, 2026. This milestone reflects the company's progress and robust financial standing, particularly in relation to its lead candidate NDV-01. The Russell 3000 Index is a key benchmark for U.S. equity performance, covering a significant portion of the market.
Read more →RLMDRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Relmada Therapeutics has appointed Dr. Michael Quirk as Senior Advisor for its sepranolone program. With over 20 years of experience in neuroscience drug development, Dr. Quirk aims to advance sepranolone, a GABA receptor modulator targeting Prader-Willi Syndrome and other CNS disorders. His expertise is expected to be crucial in navigating the clinical development of this promising therapy.
Read more →RLMDRelmada Therapeutics to Present at the Jefferies Global Healthcare Conference
Relmada Therapeutics will present at the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Sergio Traversa and CFO Maged Shenouda will participate in a fireside chat on June 4. The company is focused on developing therapies for oncology and central nervous system disorders, with promising candidates in mid-stage clinical development.
Read more →RLMDRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics reported strong Phase 2 data for NDV-01, showing a 95% complete response rate in high-risk NMIBC patients. The company is on track to initiate the Phase 3 RESCUE program in mid-2026 and has secured a $160 million PIPE financing to support its operations through 2029. Additionally, a provisional patent application for NDV-01 has been filed, potentially extending patent protection until 2047.
Read more →RLMD▲ +6.9%on this news
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Relmada Therapeutics, a clinical-stage biotechnology company, will report its first quarter 2026 financial results on May 12, 2026. The company will host a conference call and webcast at 4:30 PM ET to discuss these results and recent business progress. Relmada focuses on therapies for oncology and central nervous system disorders.
Read more →RLMDRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026
Relmada Therapeutics will present two abstracts on NDV-01 at AUA2026, including 12-month Phase 2 data for high-risk non-muscle invasive bladder cancer (NMIBC) and an overview of the upcoming Phase 3 'RESCUE' program. The presentations are scheduled for May 15 and May 17, 2026, in Washington D.C. NDV-01 is designed to improve treatment outcomes in NMIBC.
Read more →RLMDRelmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Relmada Therapeutics reported its fourth quarter and full year 2025 results, highlighting substantial advancements in its lead program, NDV-01, for treating non-muscle invasive bladder cancer. The company noted promising 12-month data demonstrating durable responses and a favorable safety profile. With a successful financing round and FDA alignment on development pathways, Relmada is poised to initiate the Phase 3 RESCUE program in mid-2026.
Read more →RLMDRelmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
Relmada Therapeutics has announced a conference call scheduled for March 19, 2026, to discuss its fourth-quarter financial results for 2025. The call will provide insights into the company's recent business progress and developments in its clinical-stage therapies. Relmada focuses on innovative treatments for oncology and central nervous system disorders.
Read more →RLMD▲ +61.1%on this newsshared move
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
Relmada Therapeutics has announced a successful oversubscribed private placement financing, raising approximately $160 million. The financing involves the sale of common stock and pre-funded warrants, with participation from several prominent investors. The funds will be utilized for working capital and advancing the company's research and development efforts.
Read more →RLMD▲ +61.1%on this newsshared move
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Relmada Therapeutics reported promising 12-month interim data for NDV-01 in a Phase 2 trial for high-risk non-muscle invasive bladder cancer (NMIBC). The treatment demonstrated a 76% complete response rate, with an 80% rate in BCG-unresponsive patients. The safety profile remains favorable, with no severe adverse events reported. These results support the advancement of NDV-01 into a Phase 3 registrational program expected to start in mid-2026.
Read more →RLMD▲ +61.1%on this newsshared move
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Relmada Therapeutics, Inc. has announced its participation in the Leerink Partners Global Healthcare Conference taking place from March 8-11, 2026, in Miami, Florida. CEO Sergio Traversa and CFO Maged Shenouda will engage in a fireside chat on March 10. The company will also offer opportunities for one-on-one meetings with investors during the event. This participation highlights Relmada's ongoing efforts to connect with the investment community and discuss its clinical-stage therapies.
Read more →RLMDRelmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Relmada Therapeutics has announced regulatory feedback from the FDA aligning on the design for registrational studies of NDV-01, aimed at treating non-muscle invasive bladder cancer (NMIBC). The FDA has approved a single-arm trial for high-grade, BCG-unresponsive NMIBC and a randomized study for intermediate-risk NMIBC. Both studies are expected to start in the first half of 2026. The company views this as a significant step forward in developing a potentially transformative therapeutic option for patients with limited treatment alternatives.
Read more →RLMDRelmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Relmada Therapeutics announced the presentation of 6-month follow-up data from its Phase 2 trial of NDV-01 for non-muscle invasive bladder cancer (NMIBC) at the Society for Urologic Oncology meeting. The data indicates a 92% complete response rate, and the company plans to initiate Phase 3 studies in H1 2026. NDV-01 is designed to provide a bladder-sparing treatment option for patients.
Read more →RLMDRelmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Relmada Therapeutics reported strong third quarter results, highlighting a 92% response rate for NDV-01 in non-muscle invasive bladder cancer (NMIBC). The company secured FDA alignment for a Phase 3 program with two distinct paths for approval. Additionally, a $100 million financing was completed to support ongoing operations and clinical trials. The company aims to initiate registrational studies in the first half of 2026.
Read more →RLMDRelmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Relmada Therapeutics, a clinical-stage biotechnology company, will report its third quarter 2025 financial results on November 13, 2025. The company is focused on developing therapies for oncology and central nervous system conditions. A conference call and webcast will provide insights into their financial performance and recent business developments.
Read more →About Relmada Therapeutics, Inc.
Headquarters2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, FL, 33134
BIOPHARMAWATCH ELITE PLUS
Trade the next RLMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime